Cell and gene therapy venture capital and public funding deal count vs Novel active substance launches
Cell and gene therapy venture capital and public funding deal count and Novel active substance launches worldwide, compared over time.
Change the pair
Compare different indicators
The series
Over time
Global, spaced by time. Both series are in count, so they share one axis; the legend names each line.
Cell and gene therapy venture capital and public funding deal count and Novel active substance launches
Unit: count · 5 observations
View the underlying data
| Indicator | Period | Type | Value |
|---|---|---|---|
| Cell and gene therapy venture capital and public funding deal count | 2023 | Actual | 96 |
| Cell and gene therapy venture capital and public funding deal count | 2022 | Actual | 97 |
| Cell and gene therapy venture capital and public funding deal count | 2021 | Actual | 127 |
| Novel active substance launches | 2025 | Actual | 79 |
| Novel active substance launches | 2004–2023 | Actual | 942 |
Source: IQVIA, IFPMA · CC BY 4.0 · Cell and gene therapy venture capital and public funding deal count · Novel active substance launches
Provenance
Where these numbers come from
Cell and gene therapy venture capital and public funding deal count
Number of venture capital and public funding transactions for cell and gene therapies in a given year.
3 observations in Global · source organisations: IQVIA
Novel active substance launches
Total number of novel active substances launched.
2 observations in Global · source organisations: IFPMA, IQVIA
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring